FDA Grants Orphan Drug Designation to APG-2575 for Treatment of Waldenström Macroglobulinemia

July 15, 2020

The FDA has granted an Orphan Drug designation to APG-2575 for the treatment of patients with Waldenström macroglobulinemia.

Hyper-CVAD Plus Ofatumumab Demonstrates Activity in Ph-Negative, CD20-Positive B-Cell ALL

July 15, 2020

“In this single-arm, phase 2 study, the combination of ofatumumab with the hyper-CVAD regimen resulted in a high proportion of adult patients with Ph-negative CD20- positive B-cell acute lymphoblastic leukemia having durable remission and long-term survival…"

Margolimab Generates Hope for Patients With Myelodysplastic Syndromes, AML

July 08, 2020

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the safety and efficacy findings of margolimab as treatment of patients with TP53-positive AML and high-risk MDS.

FDA Approves Decitabine Plus Cedazuridine for MDS With Multiple Indications

July 07, 2020

FDA has granted approval to the combination regimen decitabine and cedazuridine as treatment of adult patients with myelodysplastic syndromes under multiple indications.

Disparities Seen in Hematologic Cancer Incidence and Survival for Hispanic Patients in Texas

June 22, 2020

“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."

Ropeginterferon Provides Improved Hematocrit Control Over Phlebotomy Alone in Low-Risk PV

June 14, 2020

"This interim analysis demonstrated ropeginterferon in low-risk patients is more efficacious in keeping the hematocrit [at target levels]. In addition, we get a better quality of life and the target was reached with a reduction of phlebotomy needs."

Eprenetapopt Plus Azacitidine Yields Promising Responses in High-Risk MDS/AML

June 14, 2020

"The data from this ongoing trial of eprenetapopt with azacitidine continue to be very encouraging in these most difficult-to-treat [patients with] TP53-mutant MDS and AML, who not only have at least one TP53 mutation but the majority of whom also have high risk cytogenetic abnormalities,."

Expert Discusses Novel Treatment Approach for TP53-Mutant MDS and AML

June 11, 2020

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discussed the novel agent, APR-246, and its significance for use in the patients with myelodysplastic syndrome and acute myeloid leukemia

High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma

May 30, 2020

“Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma."

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia

May 29, 2020

"The totality of data from the two trials presented at ASCO suggests that zanubrutinib may be a preferred treatment option for patients with WM, regardless of whether they have received prior treatment."